PROVIDER PROFILE · NPI 1962496885

Paul Denouden

Internal MedicinePortland, ORI

MEDICARE UTILIZATION · PART B · 2024

No data available for this provider in 2024.

PRESCRIBING · PART D · 2024

Total Rx claims

4,668

Beneficiaries

—

Total drug cost

$3.7M

Distinct drugs

112

Brand share

39.4%

Top prescribed drugs

Bictegrav/Emtricit/Tenofov Ala354 claims

Atorvastatin Calcium271 claims

Abacavir/Dolutegravir/Lamivudi174 claims

Lisinopril169 claims

Gabapentin134 claims

QUALITY · MIPS · 2024

No data available for this provider in 2024.

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

No data available for this provider in 2024.

REFERRAL NETWORK

Where Paul Denouden's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 4 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Quest Diagnostics Clinical Laboratories Inc Clinical Laboratory · Seattle, WA	41	270
Unilab Corporation Clinical Laboratory · West Hills, CA	19	52
NPI 1124130653	15	42
Quest Diagnostics Clinical Laboratories Inc Clinical Laboratory · Portland, OR	14	43

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history